Article
Development and Validation of an LC-MS/MS Method to Quantify Gilteritinib and Its Clinical Application in Patients With FLT3 Mutation-Positive Acute Myelogenous Leukemia.
Therapeutic drug monitoring - 1 Aug 2022
Zhang Mengyu, Tajima Soichiro, Suetsugu Kimitaka, Hirota Takeshi, Tsuchiya Yuichi, Yamauchi Takuji, Yoshimoto Goichi, Miyamoto Toshihiro, Egashira Nobuaki, Akashi Koichi, Ieiri Ichiro
Abstract excerpt
BACKGROUND: Gilteritinib, a novel oral tyrosine kinase inhibitor, is used to treat acute myeloid leukemia (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations. Therapeutic drug monitoring (TDM) of gilteritinib is important for improving clinical outcomes and ensuring safety. Therefore, this study aimed to develop a simplified method for quantifying gilteritinib in human plasma using liquid chromatography-tandem...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.